Life Science News

Sirona Biochem Corp . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (" Sirona ") is very pleased to announce that Linda Pullan of Pullan Consulting will be providing strategic direction with the negotiations and licensing of TFC-1067.

Sirona is in the negotiation phase with a global top 10 pharmaceutical company for the rights to TFC-1067. Simultaneously, the company is completing the legal due diligence regarding contracts and patents, which is a straightforward task. The pharma company is advancing on the project as expected and has been transparent with next steps and timelines.

"We are thrilled to have Pullan Consulting on board to assist us with this task. Linda has successfully closed 65 pharma/biotech deals and has advised on many more. She is a renowned professional in the field," said Howard Verrico , CEO of Sirona Biochem. "We are dealing with a pharmaceutical company that is very experienced in licensing negotiations. The highest level of expertise is needed to obtain the best outcome. We see this level in Pullan Consulting and look forward to working with their team to close an optimal deal."

About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.

Sirona's compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona's laboratory, TFChem, is in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com .

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise.  Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.

SOURCE Sirona Biochem Corp.

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/December2021/16/c3558.html

News Provided by Canada Newswire via QuoteMedia

SBM:CA
Sirona Biochem Inc.

Sirona Biochem Inc.

Overview

Sirona Biochem Inc. (TSXV:SBM) is a biotechnology company with an innovative platform for developing safer, more effective cosmetic and pharmaceutical active ingredients. The technology is based on proprietary fluorination chemistry developed by the company’s wholly-owned French subsidiary, research and development (R&D) laboratory TFChem. Sirona Biochem’s business model centers on leveraging its technology platform and chemistry expertise to build strategic R&D partnerships with leading global companies through contract services, licensing and royalty agreements as well as joint ventures.

TFChem has developed a fluorination chemistry that can improve the safety and efficacy of carbohydrate-based molecules. Carbohydrate-based molecules are valuable in that they have broad application potential for the development of pharmaceuticals and cosmeceuticals. Examples of commercially available carbohydrate-based drugs include viral neuraminidase inhibitor Tamiflu, and Johnson & Johnson’s (NYSE:JNJ) SGLT2 inhibitor Invokana™. However, carbohydrate-based molecules are extremely challenging to develop due to their inherent instability. Sirona Biochem’s proprietary chemistry technique overcomes that challenge by stabilizing carbohydrates, allowing the company to explore commercial opportunities for these valuable molecules.

Sirona Biochem’s product pipeline includes an SGLT2 inhibitor for the treatment of type 2 diabetes as well as cosmeceuticals such as compound libraries for safe and effective skin lighteners and anti-aging compounds. The company has completed two successful licensing agreements. The first, for its SGLT2 inhibitor to Wanbang/Fosun Pharmaceutical in China, which is now in advanced Phase I clinical trials. The second was a non-exclusive license to Rodan + Fields, the leading skin care brand in the United States, for Sirona’s skin lightening compound TFC-1067. The compound has proven safe and effective in clinical trials.

Sirona Biochem is led by a highly experienced team of finance and biotechnology professionals. The company’s Chief Scientific Officer Dr. Géraldine Deliencourt-Godefroy is an award-winning synthetic chemist and the founder of the French biotechnology company TFChem. Her scientific research in carbohydrate chemistry has led to the discovery of new drug families and the development of drug candidates for diabetes and obesity, cosmetic ingredients and biological adjuvants. She is the recipient of the acclaimed Francinov Research and Innovation Medal, the French Ministry of Research Award and the French Senate Award.

Keep reading... Show less
Sirona Biochem Antiviral Compounds to be Tested Against SARS-CoV-2 by Top US Testing Facility

Sirona Biochem Antiviral Compounds to be Tested Against SARS-CoV-2 by Top US Testing Facility

Sirona Biochem Corp . (TSXV: SBM) (FSE: ZSB) (OTC: SRBCF) (" Sirona ") announces the advancement of 20 antiviral compounds to In Vitro testing. The compounds will be shipped to the Utah State University's Institute of Antiviral Research for evaluation against the SARS-CoV-2 virus (COVID-19).

Keep reading... Show less
Sirona Biochem Provides Update on SGLT2 Inhibitor for Type 2 Diabetes in China

Sirona Biochem Provides Update on SGLT2 Inhibitor for Type 2 Diabetes in China

Sirona Biochem Corp . (TSXV: SBM) (FSE: ZSB) (OTC: SRBCF) (" Sirona ") announces that it has received notice that the development of Sirona's SGLT2 inhibitor, TFC-039, will be discontinued by Wanbang Biopharmaceuticals (" Wanbang ") as a treatment for type 2 diabetes in China .

Keep reading... Show less
sbm tsx

Sirona Biochem Announces 2021 Annual Meeting Results: Shareholders Approve All Resolutions With Majority Vote

Sirona Biochem Corp . (TSXV: SBM) (FSE: ZSB) (OTC: SRBCF)  (" Sirona ") is pleased to announce the voting results from its Annual General Meeting of Shareholders (the "Meeting"), held in Vancouver, British Columbia on November 10, 2021 . The total number of shares represented by shareholders present in person and by proxy at the meeting was 33,335,079, representing 14.45% of Sirona's issued and outstanding Common Shares.

Keep reading... Show less
sirona biochem

/R E P E A T -- Sirona Biochem: Investing News Network Interview with CEO, Dr. Howard Verrico/

Featuring an update on anticipated deal for TFC-1067

Sirona Biochem Corp . (TSXV: SBM) (FSE: ZSB) (US-OTC: SRBCF) (" Sirona ") is pleased to inform its shareholders that a video interview with CEO, Dr. Howard Verrico has been published by Investing News Network https:investingnews.com in Vancouver BC Canada .

Keep reading... Show less

Sirona Biochem: Investing News Network Interview with CEO, Dr. Howard Verrico

Featuring an update on anticipated deal for TFC-1067

Sirona Biochem Corp . (TSXV: SBM) (FSE: ZSB) (US-OTC: SRBCF) (" Sirona ") is pleased to inform its shareholders that a video interview with CEO, Dr. Howard Verrico has been published by Investing News Network https:investingnews.com in Vancouver BC Canada .

Keep reading... Show less

ABBV ALERT: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against AbbVie, Inc.

The law firm of Kessler Topaz Meltzer & Check, LLP(www.ktmc.com) informs investors that the firm has filed a securities class action lawsuit against ABBVie, Inc. (ABBVie) (NYSE:ABBV) on behalf of all persons and entities who purchased or otherwise acquired ABBVie securities between April 30, 2021, and August 31, 2021, inclusive (the "Class Period

CLICK HERE TO SUBMIT YOUR ABBVIE LOSSES. YOU CAN ALSO CLICK ON THE FOLLOWING LINK OR COPY AND PASTE IN YOUR BROWSER: https://www.ktmc.com/new-cases/abbvie-inc?utm_source=PR&utm_medium=link&utm_campaign=abbvie&mktm=r

Keep reading... Show less

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ABBV, NTRA and CDNA

The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff

ABBVie Inc. (NYSE:ABBV)
Class Period: April 30, 2021 - August 31, 2021
Lead Plaintiff Deadline: June 6, 2022

Keep reading... Show less

CLASS ACTION UPDATE for VLTA, LCID and AUPH: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you

VLTA Shareholders Click Here: https://www.zlk.com/pslra-1/volta-inc-loss-submission-form?prid=27706&wire=1
LCID Shareholders Click Here: https://www.zlk.com/pslra-1/lucid-group-inc-loss-submission-form?prid=27706&wire=1
AUPH Shareholders Click Here: https://www.zlk.com/pslra-1/aurinia-pharmaceuticals-inc-information-loss-submission-form?prid=27706&wire=1

Keep reading... Show less

Aptose to Provide Program Updates at KOL Webinar on Thursday, June 2nd

Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that it will host a key opinion leader (KOL) webinar on HM43239 and luxeptinib and their roles in the treatment of acute myeloid leukemia (AML) on Thursday, June 2, 2022 at 4:30 pm Eastern Time.

The call will feature KOLs Brian Druker, M.D., of the Oregon Health & Science University, Naval G. Daver, M.D., of The University of Texas MD Anderson Cancer Center, and Brian Andrew Jonas, M.D., Ph.D., of the University of California, Davis, who will discuss the current treatment landscape and unmet medical need in treating patients with acute myeloid leukemia AML, as well as their experiences with Aptose's investigational therapies.

Keep reading... Show less

AbbVie to Present at the Bernstein 38th Annual Strategic Decisions Conference

ABBVie (NYSE: ABBV) will participate in the Bernstein 38 th Annual Strategic Decisions Conference on Wednesday, June 1, 2022 . Richard A. Gonzalez chairman and chief executive officer, will present at 10:00 a.m. Central Time .

A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.

Keep reading... Show less

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of ABBV, AXSM and CDNA

The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery

ABBVie Inc. (NYSE:ABBV)

Keep reading... Show less

Latest Press Releases

Related News

×